Loading
A phase 3 trial testing Givinostat in myeloproliferative neoplasms, now recruiting.
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera is a phase 3 interventional study registered as NCT06093672, led by Italfarmaco with PPD Development, LP, and recruiting on the registry. Official title: Randomised, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL. Planned enrolment is 220 participants (estimated). The study started in 2024-03-26 and primary completion is expected in 2026-07. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Italfarmaco, Givinostat, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/